Reshaping the HIV treatment and prevention landscape
Relaunch of Shingrix post COVID-19 vaccine roll out
gsk
~50% intend to receive Shingrix <3M post COVID Vx | New US prescriptions recovering in 65+ age group
Time between receiving COVID-19 vaccine and Shingles vaccine
NBRx & (%) of 65+ Completed COVID-19 Vaccination
May '21
(n=44)
After 1-2 weeks
3%
After 3-4 weeks
After 2-3 months
After 4-6 months
60
65+ Shingrix
NBRX (000s)
80
75%
74%
60
51
49
50
66%
68% 71%
72%
70
60%
9%
53%
% of 65+ Patients
Completed
COVID Series
60
40
38
36%
34
39
50
41%
35
39%
32
34%
31
40
23%
28
30
25
29%
28
27
24%
30
23
19%
22
120
21
14%
20
18
20
16
14%
10
8% 15
14 14
5%
10
2%
11
0% 1%
More than 6 months after
8%
Whenever my doctor advises
6%
Not sure
Source: US Market Research, May 2021, IPSOS
0
12/25/2020 1/8/2021 1/22/2021 2/5/2021 2/19/2021 3/5/2021 3/19/2021 4/2/2021 4/16/2021 4/30/2021 5/14/2021 5/28/2021
COVID-19 Patients (Millions) Fully Vaccinated
NBRX: IQVIA New to Brand Weekly data (28/5)
CDC (https://covid.cdc.gov/covid-data-tracker/#vaccinations)
Shingrix 65+ NBRx (000s)
37View entire presentation